Veritas Asset Management Llp Has Cut Waters (WAT) Position; Adamis Pharmaceuticals (ADMP) Had 3 Bullish Analysts

November 14, 2017 - By Nellie Frank

Among 3 analysts covering Adamis Pharma (NASDAQ:ADMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 7 analyst reports since December 1, 2015 according to SRatingsIntel.

The stock of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) earned “Buy” rating by Maxim Group on Monday, August 21. Maxim Group maintained it with “Buy” rating and $1000 target in Monday, June 12 report. Raymond James initiated Adamis Pharmaceuticals Corp (NASDAQ:ADMP) on Tuesday, September 12 with “Buy” rating. Maxim Group maintained the shares of ADMP in report on Thursday, July 21 with “Buy” rating. As per Tuesday, December 1, the company rating was initiated by Maxim Group. See Adamis Pharmaceuticals Corp (NASDAQ:ADMP) latest ratings:

04/10/2017 Broker: B. Riley & Co Rating: Buy New Target: $9.5
12/09/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Initiate
21/08/2017 Broker: Maxim Group Rating: Buy New Target: $13.0 Maintain
12/06/2017 Broker: Maxim Group Rating: Buy New Target: $10.0000 Maintain

Veritas Asset Management Llp decreased Waters Corp (WAT) stake by 0.64% reported in 2017Q2 SEC filing. Veritas Asset Management Llp sold 15,466 shares as Waters Corp (WAT)’s stock rose 13.72%. The Veritas Asset Management Llp holds 2.40M shares with $440.92 million value, down from 2.41 million last quarter. Waters Corp now has $15.56 billion valuation. The stock increased 0.51% or $1 during the last trading session, reaching $195.64. About 342,869 shares traded. Waters Corporation (NYSE:WAT) has risen 30.08% since November 14, 2016 and is uptrending. It has outperformed by 13.38% the S&P500.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The company has market cap of $145.78 million. The Firm is engaged in the development of its specialty pharmaceutical products. It currently has negative earnings. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company .

The stock increased 2.20% or $0.1 during the last trading session, reaching $4.65. About 633,793 shares traded or 3.02% up from the average. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has declined 52.09% since November 14, 2016 and is downtrending. It has underperformed by 68.79% the S&P500.

Veritas Asset Management Llp increased Microsoft Corp (NASDAQ:MSFT) stake by 847,716 shares to 10.34M valued at $712.74M in 2017Q2. It also upped Cvs Health Corp (NYSE:CVS) stake by 865,756 shares and now owns 8.44 million shares. Charter Communications Inc was raised too.

Since May 18, 2017, it had 0 insider buys, and 7 selling transactions for $15.34 million activity. $4.21 million worth of Waters Corporation (NYSE:WAT) was sold by Harrington Michael C. Rae Elizabeth B sold $2.84 million worth of Waters Corporation (NYSE:WAT) on Wednesday, May 24. The insider Khanna Rohit sold 10,000 shares worth $1.83M. $843,720 worth of Waters Corporation (NYSE:WAT) shares were sold by GLIMCHER LAURIE H M.D.. 4,280 shares were sold by Cassis Eugene G, worth $788,666.

Among 15 analysts covering Waters Corporation (NYSE:WAT), 5 have Buy rating, 1 Sell and 9 Hold. Therefore 33% are positive. Waters Corporation had 44 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Waters Corporation (NYSE:WAT) earned “Hold” rating by Deutsche Bank on Thursday, January 7. The stock has “Neutral” rating by Bank of America on Friday, November 10. The firm earned “Outperform” rating on Thursday, November 10 by Leerink Swann. On Monday, October 2 the stock rating was maintained by Robert W. Baird with “Buy”. The stock has “Hold” rating by Deutsche Bank on Wednesday, October 25. The firm earned “Buy” rating on Monday, August 24 by Zacks. Cantor Fitzgerald maintained the shares of WAT in report on Wednesday, April 26 with “Buy” rating. On Wednesday, October 25 the stock rating was maintained by Citigroup with “Neutral”. The company was maintained on Wednesday, July 27 by Citigroup. The stock of Waters Corporation (NYSE:WAT) has “Hold” rating given on Friday, October 6 by Jefferies.

Investors sentiment increased to 1.08 in Q2 2017. Its up 0.23, from 0.85 in 2017Q1. It increased, as 20 investors sold WAT shares while 179 reduced holdings. 84 funds opened positions while 131 raised stakes. 71.38 million shares or 0.03% more from 71.36 million shares in 2017Q1 were reported. Utah Retirement reported 13,918 shares or 0.06% of all its holdings. Pnc Ser Grp owns 0% invested in Waters Corporation (NYSE:WAT) for 8,998 shares. Autus Asset Management Limited Liability Company invested in 1,217 shares or 0.05% of the stock. Sheets Smith Wealth holds 1.47% or 30,258 shares in its portfolio. Clarkston Capital Prtn Ltd Liability has 253,928 shares for 2.08% of their portfolio. Diversified reported 1,285 shares. Kentucky Retirement Insur Tru Fund has 2,192 shares for 0.07% of their portfolio. Brown Advisory Inc stated it has 0% in Waters Corporation (NYSE:WAT). Pennsylvania-based Logan Cap has invested 1.01% in Waters Corporation (NYSE:WAT). Retail Bank Of America Corp De holds 0.01% or 408,284 shares in its portfolio. Conning Inc reported 1,988 shares. Mitchell Mcleod Pugh Williams has 1,770 shares for 0.25% of their portfolio. Axa holds 0.03% or 38,795 shares. 19,116 were accumulated by Shell Asset Management Communications. Farmers Merchants owns 126 shares for 0% of their portfolio.

Analysts await Waters Corporation (NYSE:WAT) to report earnings on January, 23. They expect $2.44 earnings per share, up 10.41% or $0.23 from last year’s $2.21 per share. WAT’s profit will be $194.06M for 20.05 P/E if the $2.44 EPS becomes a reality. After $1.77 actual earnings per share reported by Waters Corporation for the previous quarter, Wall Street now forecasts 37.85% EPS growth.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>